Cham Gregory, Lim Francis, Earnest Arul, Gopalakrishnakone Ponnampalam
Emergency Medicine Department, Alexandra Hospital, 378 Alexandra Road, Singapore 159964.
ISRN Toxicol. 2013 Aug 12;2013:247645. doi: 10.1155/2013/247645. eCollection 2013.
Naja sumatrana is the dominant cobra species in Malaysia, Singapore, Borneo, and Sumatra, and it does not have specific antivenom. The Haffkine antivenom has been advocated instead. This study aims to determine the efficacy of this antivenom against Naja sumatrana envenoming using a mouse model. Methods. Male Swiss albino mice were used. Intravenous LD50 was first determined separately for Naja naja and Naja sumatrana venom. ED50 was determined by preincubating antivenom with each venom at 2.5 LD50 before administering the mixture into the tail vein. Validation was carried out using a challenge test. Each mouse received 111 µg of Naja sumatrana venom intramuscularly followed by intraperitoneal administration of dilute Haffkine antivenom. Survival was recorded 24 hours after envenoming. Results. The LD50 of Naja naja venom was 78.13 µg, standard error (SE) 13.3 µg. The ED50 of the Haffkine antivenom against Naja naja venom was 45.9 mg, SE 7.5 mg. The LD50 and ED50 of Naja sumatrana venom were 55.5 µg, SE 12.0 µg; and 73.9 mg, SE 12.0 mg, respectively. The intra-peritoneal ED50 against 111 µg intramuscular Naja sumatrana venom was 136.95 mg, SE 36.74 mg. Conclusion. The Haffkine polyvalent antivenom exhibited cross-neutralisation against Naja sumatrana venom when used at a higher dose.
马来环蛇是马来西亚、新加坡、婆罗洲和苏门答腊的主要眼镜蛇种类,且没有特定的抗蛇毒血清。相反,有人主张使用哈夫金抗蛇毒血清。本研究旨在使用小鼠模型确定这种抗蛇毒血清对马来环蛇毒液中毒的疗效。方法。使用雄性瑞士白化小鼠。首先分别测定眼镜蛇和马来环蛇毒液的静脉注射半数致死量(LD50)。在将混合物注入尾静脉之前,通过将抗蛇毒血清与每种毒液在2.5倍LD50下预孵育来测定半数有效量(ED50)。使用激发试验进行验证。每只小鼠肌肉注射111微克马来环蛇毒液,随后腹腔注射稀释的哈夫金抗蛇毒血清。在中毒后24小时记录存活情况。结果。眼镜蛇毒液的LD50为78.13微克,标准误(SE)为13.3微克。哈夫金抗蛇毒血清对眼镜蛇毒液的ED50为45.9毫克,SE为7.5毫克。马来环蛇毒液的LD50和ED50分别为55.5微克,SE为12.0微克;以及73.9毫克,SE为12.0毫克。针对111微克肌肉注射的马来环蛇毒液的腹腔ED50为136.95毫克,SE为36.74毫克。结论。哈夫金多价抗蛇毒血清在高剂量使用时对马来环蛇毒液表现出交叉中和作用。